Immunity Pharma Ltd.
Immunity Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, initially targeting ALS. Their approach involves biologically active peptides that stimulate therapeutic cell-signaling processes, aiming to mitigate disease progression by inducing survival-supporting processes. Their lead candidate, IPL344, is an intravenous drug that activates the Akt pathway, which is down-regulated in ALS and other neurodegenerative disorders. The company is committed to advancing clinical trials and developing innovative treatments to address unmet medical needs in neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Immunity Pharma Ltd.
28 Miron Street, Mevasseret Zion, Israel 90805
Patents
Products
Peptide Akt activator (lead clinical candidate)
A biologically active peptide developed to activate the intracellular Akt signaling pathway, administered by intravenous bolus and evaluated in Phase 1/2a clinical studies for the treatment of amyotrophic lateral sclerosis (ALS).
Peptide Akt activator (lead clinical candidate)
A biologically active peptide developed to activate the intracellular Akt signaling pathway, administered by intravenous bolus and evaluated in Phase 1/2a clinical studies for the treatment of amyotrophic lateral sclerosis (ALS).
Expertise Areas
- Clinical trial management for neurology indications (Phase 1/2a)
- Peptide therapeutic discovery and development
- Biomarker development and assay validation
- Preclinical efficacy testing in ALS models
Key Technologies
- Akt pathway activation
- Peptide therapeutics
- Intravenous bolus administration (home-based)
- Pharmacodynamic biomarker assays (Akt activation)
News & Updates
The presentation of new data supporting IPL344's efficacy in ALS, including clinical trial results and biomarker analysis.
The company announced positive results from a Phase 2a clinical trial demonstrating that IPL344 was well tolerated and showed signs of slowing disease progression in ALS patients.
Biomarker data indicating a reduction in plasma neurofilament light chain levels following IPL344 treatment, suggesting a slowdown of neuronal injury.
Early indications of efficacy and safety from a Phase 1/2a study, including slowed disease progression and biomarker engagement.
The drug IPL344 received orphan drug designation, providing incentives and exclusivity for its development as a treatment for ALS.
The company announced the start of a clinical trial to evaluate the safety and efficacy of IPL344 in ALS patients.
The presentation of new data supporting IPL344's efficacy in ALS, including clinical trial results and biomarker analysis.
The company announced positive results from a Phase 2a clinical trial demonstrating that IPL344 was well tolerated and showed signs of slowing disease progression in ALS patients.
Biomarker data indicating a reduction in plasma neurofilament light chain levels following IPL344 treatment, suggesting a slowdown of neuronal injury.
Early indications of efficacy and safety from a Phase 1/2a study, including slowed disease progression and biomarker engagement.
The drug IPL344 received orphan drug designation, providing incentives and exclusivity for its development as a treatment for ALS.
The company announced the start of a clinical trial to evaluate the safety and efficacy of IPL344 in ALS patients.